Image may be NSFW.
Clik here to view.
Clik here to view.
Dr Paolo Paoletti, president, Oncology, GSK
GlaxoSmithKline (GSK) announced that the USFDA has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anaemia (SAA), who have had an insufficient response to immunosuppressive -
